CareDx, Inc. (NASDAQ:CDNA) is expected to report third quarter earnings results, after market close, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.06 per share.
Looking ahead, the full year loss are expected at $ 0.11 per share on the revenues of $ 184.30 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 53.00 million ~ $ 53.00 million
Full Year 2020 topline are forecasted in a range of$ 165.00 million ~ $ 168.00 million
Click Here For More Historical Outlooks Of CareDx, Inc.
Previous Quarter Performance
CareDx, Inc. recorded income for the second quarter of $ 0.04 per share, from the revenue of $ 41.80 million. The quarterly revenues extended 49.07 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.04 per share from $ 35.61 million in revenue. The bottom line results beat street analysts by $ 0.08 or 200.00 percent, at the same time, top line results outshined analysts by $ 6.19 million or 17.38 percent.
Stock Performance
Shares of CareDx, Inc. traded low $ -0.23 or -0.45 percent on Wednesday, reaching $ 50.64 with volume of 398.90 thousand shares. CareDx, Inc. has traded high as $ 51.43 and has cracked $ 48.66 on the downward trend
According to the previous trading day, closing price of $ 50.64, representing a 290.11 % increase from the 52 week low of $ 13.04 and a 7.26 % decrease over the 52 week high of $ 54.85.
The company has a market capital of $ 2.48 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 8th October 2020, maintained by HC Wainwright at Buy rating, with $ 47.00 target price.
- On 2nd October 2020, maintained by HC Wainwright at Buy rating, with $ 45.00 target price.
Conference Call
CareDx, Inc. will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.caredxinc.com
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients.
